174 related articles for article (PubMed ID: 37548421)
1. Telomere Shortening of Barrett's Esophagus and Esophageal Adenocarcinoma in Japanese Patients.
Tahara T; Shijimaya T; Yamazaki J; Tomiyama T; Fukui T; Naganuma M
Cancer Invest; 2023 Sep; 41(7):640-645. PubMed ID: 37548421
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive DNA methylation profiling of Barrett's esophagus and esophageal adenocarcinoma in Japanese patients.
Shijimaya T; Tahara T; Yamazaki J; Matsumoto Y; Nakamura N; Takahashi Y; Tomiyama T; Fukui T; Shibata T; Naganuma M
Mol Carcinog; 2023 Aug; 62(8):1191-1200. PubMed ID: 37204209
[TBL] [Abstract][Full Text] [Related]
3. Telomere shortening accelerates tumor initiation in the L2-IL1B mouse model of Barrett esophagus and emerges as a possible biomarker.
Sahm V; Maurer C; Baumeister T; Anand A; Strangmann J; Schmid RM; Wang TC; Quante M
Oncotarget; 2022; 13():347-359. PubMed ID: 35178191
[TBL] [Abstract][Full Text] [Related]
4. Leukocyte telomere length in relation to the risk of Barrett's esophagus and esophageal adenocarcinoma.
Wennerström EC; Risques RA; Prunkard D; Giffen C; Corley DA; Murray LJ; Whiteman DC; Wu AH; Bernstein L; Ye W; Chow WH; Vaughan TL; Liao LM
Cancer Med; 2016 Sep; 5(9):2657-65. PubMed ID: 27384379
[TBL] [Abstract][Full Text] [Related]
5. Genetic profiles of Barrett's esophagus and esophageal adenocarcinoma in Japanese patients.
Tokunaga M; Okimoto K; Akizue N; Ishikawa K; Hirotsu Y; Amemiya K; Ota M; Matsusaka K; Nishimura M; Matsushita K; Ishikawa T; Nagashima A; Shiratori W; Kaneko T; Oura H; Kanayama K; Ohta Y; Taida T; Saito K; Matsumura T; Chiba T; Mochizuki H; Arai M; Kato J; Ikeda JI; Omata M; Kato N
Sci Rep; 2021 Sep; 11(1):17671. PubMed ID: 34480065
[TBL] [Abstract][Full Text] [Related]
6. Leukocyte telomere length predicts cancer risk in Barrett's esophagus.
Risques RA; Vaughan TL; Li X; Odze RD; Blount PL; Ayub K; Gallaher JL; Reid BJ; Rabinovitch PS
Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2649-55. PubMed ID: 18086770
[TBL] [Abstract][Full Text] [Related]
7. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
[TBL] [Abstract][Full Text] [Related]
8. Chromosomal instability in Barrett's esophagus is related to telomere shortening.
Finley JC; Reid BJ; Odze RD; Sanchez CA; Galipeau P; Li X; Self SG; Gollahon KA; Blount PL; Rabinovitch PS
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1451-7. PubMed ID: 16896031
[TBL] [Abstract][Full Text] [Related]
9. Microarchitectures of Barrett's esophagus associated with DNA methylation status.
Shijimaya T; Tahara T; Yamazaki J; Kobayashi S; Horitani A; Matsumoto Y; Nakamura N; Okazaki T; Takahashi Y; Tomiyama T; Honzawa Y; Fukata N; Fukui T; Naganuma M
Epigenomics; 2023 Aug; 15(15):759-767. PubMed ID: 37661863
[No Abstract] [Full Text] [Related]
10. Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort.
Gaddam S; Singh M; Balasubramanian G; Thota P; Gupta N; Wani S; Higbee AD; Mathur SC; Horwhat JD; Rastogi A; Young PE; Cash BD; Bansal A; Vargo JJ; Falk GW; Lieberman DA; Sampliner RE; Sharma P
Gastroenterology; 2013 Sep; 145(3):548-53.e1. PubMed ID: 23714382
[TBL] [Abstract][Full Text] [Related]
11. [Endoscopic diagnosis of Barrett's adenocarcinoma].
Yoshio H; Takashi Y; Mitsuyo H; Nobuhiko Y; Tatsurou T; Kazuhiko S; Yoko H; Shigemasa I; Hisanaga M; Osamu H; Katsuyoshi S; Seishi U; Matsushita H; Masahiko T
Nihon Geka Gakkai Zasshi; 1999 Mar; 100(3):244-8. PubMed ID: 10379534
[TBL] [Abstract][Full Text] [Related]
12. Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: comparison with traditional long segment Barrett's esophagus.
Weston AP; Krmpotich PT; Cherian R; Dixon A; Topalosvki M
Am J Gastroenterol; 1997 Mar; 92(3):407-13. PubMed ID: 9068459
[TBL] [Abstract][Full Text] [Related]
13. Length of Barrett's oesophagus and cancer risk: implications from a large sample of patients with early oesophageal adenocarcinoma.
Pohl H; Pech O; Arash H; Stolte M; Manner H; May A; Kraywinkel K; Sonnenberg A; Ell C
Gut; 2016 Feb; 65(2):196-201. PubMed ID: 26113177
[TBL] [Abstract][Full Text] [Related]
14. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
[TBL] [Abstract][Full Text] [Related]
15. Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas.
Corley DA; Mehtani K; Quesenberry C; Zhao W; de Boer J; Weiss NS
Gastroenterology; 2013 Aug; 145(2):312-9.e1. PubMed ID: 23673354
[TBL] [Abstract][Full Text] [Related]
16. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
[TBL] [Abstract][Full Text] [Related]
17. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
[TBL] [Abstract][Full Text] [Related]
18. Endoscopic features of esophageal adenocarcinoma derived from short-segment versus long-segment Barrett's esophagus.
Yamasaki A; Shimizu T; Kawachi H; Yamamoto N; Yoshimizu S; Horiuchi Y; Ishiyama A; Yoshio T; Hirasawa T; Tsuchida T; Sasaki Y; Fujisaki J
J Gastroenterol Hepatol; 2020 Feb; 35(2):211-217. PubMed ID: 31396997
[TBL] [Abstract][Full Text] [Related]
19. Barrett's surveillance identifies patients with early esophageal adenocarcinoma.
Wong T; Tian J; Nagar AB
Am J Med; 2010 May; 123(5):462-7. PubMed ID: 20399324
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of Barrett's esophagus and expression of mucin antigens detected by a panel of monoclonal antibodies in Barrett's esophagus and esophageal adenocarcinoma in Japan.
Azuma N; Endo T; Arimura Y; Motoya S; Itoh F; Hinoda Y; Irimura T; Hosokawa M; Imai K
J Gastroenterol; 2000; 35(8):583-92. PubMed ID: 10955596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
